Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

This study has been terminated.
(toxicities)
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Gynecologic Oncology Associates
ClinicalTrials.gov Identifier:
NCT00976183
First received: September 10, 2009
Last updated: February 5, 2014
Last verified: February 2014

September 10, 2009
February 5, 2014
October 2009
June 2012   (final data collection date for primary outcome measure)
Objective Response Rate [ Time Frame: 2 years or 24 months ] [ Designated as safety issue: Yes ]
Progression Free Survival [ Time Frame: 2 years or 24 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00976183 on ClinicalTrials.gov Archive Site
Progression Free Survival [ Time Frame: 2 years or 24 months ] [ Designated as safety issue: No ]
Objective Response Rate [ Time Frame: 2 years or 24 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
A Phase I/II, Open-Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow & Curtin, 1998). Currently, no triplet regimen has demonstrated compelling superiority. Therefore, the combination of Paclitaxel, Carboplatin, and Vorinostat is intriguing because of their potential synergy, distinct mechanisms of action, and non-overlapping toxicity.

Ovarian cancer is the fifth most common cancer in women, accounting for nearly 15,280 deaths annually in the United States [1]. Paclitaxel and Carboplatin are currently the accepted standard of care for first line treatment of ovarian cancer [2, 3]. In spite of standard chemotherapy, nearly 70% of patients succumb to this disease. Consequently, studies continue to examine the activity of new agents and dosing regimens to improve disease free intervals and overall survival.

There have been recent data suggesting that weekly chemotherapy regimens may significantly benefit cancer patients' prognosis [4, 5]. Non-small cell lung cancer patient studies employing weekly regimens have shown comparable response and survival rates to Q3 weekly dosing schedules, with a more favorable toxicity profile [6, 7]. Further studies have suggested that weekly Taxane dosing is at least as effective, less toxic, and more convenient than traditional regimens [4, 8, 9].

The favorable activity associated with weekly chemotherapy has primarily been studied in recurrent ovarian cancer patients, investigating the efficacy of single and/or combination drug regimens [10, 11]. However, there have been some studies involving chemo-naïve patients [4, 12, 13]. De Jongh et al. [4} conducted a randomized I/II ovarian cancer trial with cisplatin and escalating doses of weekly or 4-weekly paclitaxel. The chemo-naïve patients exhibited a 94% overall response rate and 48 month median overall survival, while maintaining manageable toxicity. In a more recent advanced ovarian cancer study, Isonishi et al. compared the impact of paclitaxel and carboplatin administered either tri-weekly (c-TC) or dose dense weekly (dd-TC) with regard to patient progression free survival (PFS) [14]. Median PFS for the c-TC patients was 17.1 months and 27.9 months for the dd-TC group. There was also more favorable survival rates in the dose dense patients (83.6%) in comparison to the tri-weekly groups (77.7%)

Shen et al. conducted a Chinese study investigating the efficacy of combination weekly Taxol plus Carboplatin compared to Taxol given every three weeks plus Carboplatin in previously untreated ovarian cancer patients [12]. While the two regimens had equal efficacy, there was less toxicity observed in the weekly regimen. Additional studies have also indicated that lower doses and shorter infusion times inherent in weekly dosing regimens should mitigate bone marrow myelosuppression and other toxicities associated with standard paclitaxel 3-weekly administration [13].

In addition to weekly primary induction chemotherapy regimens, studies involving consolidation or maintenance therapy have been employed in the hopes of improving survival [15, 16]. Micha et al. reported significantly better progression free survival results (94 weeks vs. 45 weeks) for an ovarian cancer group who received 12 cycles of paclitaxel consolidation therapy following induction therapy, compared to a similar group who received 3 cycles of paclitaxel consolidation therapy [16].

The current pilot study was designed to determine toxicity, progression free survival, and response rate of weekly Taxol; every four-week Carboplatin; and Vorinostat (7 days on, 7 days off 7 days on, 7 days off) given for 6 cycles. Some patients will continue on consolidation therapy, which will consist of Taxol in combination with Vorinostat for an additional 12 cycles.

Modifying the dosing schedule of established chemotherapy regimens using weekly chemotherapy administration and consolidation therapy may decrease drug toxicity and maximize efficacy. These benefits are particularly intriguing in patients for whom disease treatment is long-term.

Since no triplet regimen has demonstrated compelling superiority, the combination of Taxol, Carboplatin, and Vorinostat is intriguing because of their potential synergy, distinct mechanisms of action, and non-overlapping toxicity.

Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ovarian Neoplasms
  • Drug: Vorinostat
    Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
    Other Name: suberoylanilide hydroxamic acid (SAHA)
  • Drug: Vorinostat
    Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
    Other Name: suberoylanilide hydroxamic acid (SAHA)
Experimental: Vorinostat
All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
Interventions:
  • Drug: Vorinostat
  • Drug: Vorinostat
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
19
October 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with a histologic or cytologic diagnosis of stage III/IV ovarian cancer, fallopian tube epithelial cancer, or peritoneal cancer who have not received prior chemotherapy or radiotherapy.
  • Subjects must have the appropriate surgery for their gynecologic cancer. However, subjects may be treated in a neoadjuvant manner, with surgery being performed after chemotherapy cycles 1, 2, or 3.
  • If neoadjuvant therapy is not administered, subjects must receive their first dose no more than six weeks postoperatively.
  • Subjects must have adequate bone marrow, renal and hepatic function as defined by WBC > 3,000 cells/cu ml., platelets > 100,000/cu.ml., calculated creatinine clearance > 50 ccs/min., bilirubin < 1.5 mg/dl, and SGOT < three times normal.
  • Karnofsky performance status > 50%.
  • Subjects who have signed an institutional review board (IRB) approved informed consent form.

Exclusion Criteria:

  • Subjects with epithelial ovarian cancer of low malignancy potential.
  • Subjects with septicemia, severe infection, or acute hepatitis.
  • Subjects with a history of congestive heart failure, angina, or a history of myocardial infarction within the past six months.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00976183
GOA-TCOV
No
Gynecologic Oncology Associates
Gynecologic Oncology Associates
Merck Sharp & Dohme Corp.
Principal Investigator: John Micha, MD Gynecologic Oncology Associates
Gynecologic Oncology Associates
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP